The latest update is out from Optimi Health ( (TSE:OPTI) ).
Optimi Health has completed its largest production batch of over 4,000 GMP-grade MDMA capsules, aimed at treating more than 1,000 patients globally. The company has also extended the shelf life of its MDMA capsules to one year and launched a two-year stability program to ensure long-term quality. With increasing demand from Australia, Canada, and an upcoming Phase 2 clinical trial in Israel, Optimi is well-positioned to meet the growing needs for cost-effective, psychedelic-assisted therapy, reinforcing its commitment to expanding access to such treatments.
More about Optimi Health
Optimi Health Corp is a Canadian-based company licensed by Health Canada, focusing on the production and supply of natural, GMP-grade psilocybin and MDMA. It is one of the few companies capable of manufacturing psychedelic drugs in-house and exporting them globally, with a market focus on clinical and therapeutic applications for PTSD treatment.
YTD Price Performance: -2.38%
Average Trading Volume: 66,823
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$19.41M
For an in-depth examination of OPTI stock, go to TipRanks’ Stock Analysis page.